Rovadicitinib: First Approval - PubMed
3 hours ago
- #drug approval
- #myelofibrosis treatment
- #JAK inhibitor
- Rovadicitinib is a JAK/ROCK inhibitor developed by Chia Tai Tianqing Pharmaceutical Group for treating myelofibrosis and other conditions.
- It received its first approval in China on 25 February 2026 for first-line treatment of adult patients with intermediate-2 or higher-risk primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
- The article summarizes milestones in rovadicitinib's development leading to this approval for myelofibrosis.